Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4738763 | 0.80 | XDH (0.47) | PGRXDHSLC22A12PRF1CTSC | |
| SCHEMBL4648461 | 0.78 | XDH (0.44) | PGRXDHSLC22A12PRF1NR3C1 | |
| SCHEMBL4648526 | 0.75 | XDH (0.39) | PGRXDHSLC22A12PRF1 | |
| SCHEMBL4648231 | 0.74 | CA2 (0.42) | — | |
| SCHEMBL4648626 | 0.73 | CYP11B2 (0.37) | XDHSLC22A12CTSC | |
| SCHEMBL4649007 | 0.72 | HSD17B1 (0.38) | XDHSLC22A12 | |
| SCHEMBL4648255 | 0.72 | GRIA2 (0.34) | — | |
| SCHEMBL14025338 | 0.72 | NEK1 (0.42) | PGRCTSCNR3C1NR3C2 | |
| SCHEMBL4648553 | 0.71 | PARP1 (0.41) | XDHSLC22A12 | |
| SCHEMBL4646451 | 0.71 | NRP1 (0.33) | XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | claimed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | claimed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | claimed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | FSHR, NPY1R, GNRHR | PGR 185/4885XDH 2315/4885SLC22A12 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.